RankAlpha logo
Back to Rankings

NVAX

NovavaxD
Nasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
At close
2026-07-18
View Chart
+
Peers tracked
10
U.S. public peers
Grade Position
Below peers
vs peer average
NVAX vs peer average
43/100
NVAX vs. peer average (D vs. D)
Grade spread
A 1 · C 2 · D 5 · F 1
Graded peers loaded
Coverage
10 graded
100% of tracked

Peer overview

ANAB is the first available peer comparator.

AnaptysBio is a closer small-cap biotech valuation comp than a business-model comp; it helps frame how the market discounts cash-backed pipeline optionality, but it is not a vaccine royalty story.

✓Peer source comes from the stored AI memo or peer model
✓Grades and factor rows use RankAlpha API data when available
✓Missing peer scores remain blank instead of being estimated
✓Side-by-side comparison keeps the data contract visible
Top peerANABAnaptysBio
NVAX
Novavax
ANAB
AnaptysBio
Grade
D
C
Momentum
17
87
Value
60
41
Sentiment
49
39
Setup Bias
Net —
-
Market Cap
-
-
Posture
Defensive
Mixed
Open Side-by-Side ComparisonCompare all

Grade position vs ANAB

NVAX / ANAB
Grade Position
Below peers
NVAX vs. peer average (D vs. D)
43/100
Momentum
17
ANAB
Value
60
NVAX
Sentiment
49
NVAX

Rotation landscape

Peers ranked by the order returned from the peer source, with grades from the API.

Rank
Ticker
Company
Grade
Grade score
vs NVAX
1
ANAB
ANAB
C
60/100
-1
2
IMTX
IMTX
D
40/100
Even
3
SVRA
SVRA
D
40/100
Even
4
PAHC
Phibro Animal Health Corporation Class A Common
D
40/100
Even
5
NNNN
Anbio Biotechnology Class A Common
F
20/100
+1
ANAB is the first peer returned for this comparison set.